Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: A multicenter retrospective study

Saeka Egami, Hitoshi Kawazoe, Hironobu Hashimoto, Ryuji Uozumi, Toko Arami, Naomi Sakiyama, Yuichiro Ohe, Hideo Nakada, Tohru Aomori, Shinnosuke Ikemura, Koichi Fukunaga, Masakazu Yamaguchi, Tomonori Nakamura

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Pembrolizumab is currently the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the association between immune-related adverse events (irAEs) and peripheral blood cell counts remains unclear. We aimed at identifying peripheral blood cell counts that may predict the development of pembrolizumab-induced irAEs. Methods: We retrospectively analyzed data on consecutive patients with advanced NSCLC who received pembrolizumab monotherapy as first-line or later-line therapy at the National Cancer Center Hospital and Keio University Hospital. We used data between December 2015 and November 2018. The primary endpoint was the relationship between peripheral blood cell count data and early-onset irAEs during the 6-weeks study period. Receiver operating characteristic (ROC) curve and multivariable logistic regression analyses were performed. Results: In total, 92 patients were evaluated, of whom 45 (48.9%) had at least one irAE during the first 6-weeks after treatment initiation. The ROC curves revealed that the optimal cutoff of pretreatment absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) for onset of irAEs were 1459, 2.320, 1.538, and 165, respectively. Multivariable logistic regression analyses revealed that pretreatment ALC>1450 and LMR>1.6 were significantly associated with a reduced risk for onset of any irAEs, whereas pretreatment NLR>2.3 and PLR>165 were significantly associated with an increased risk. Conclusions: The findings suggest that considering the routine availability of blood cell count data before the initiation of treatment with pembrolizumab, it may be useful in identifying early-onset irAEs during the 6-weeks study period in clinical practice.

Original languageEnglish
Pages (from-to)2105-2112
Number of pages8
JournalJournal of Cancer
Volume12
Issue number7
DOIs
Publication statusPublished - 2021 Feb 16

Keywords

  • Absolute lymphocyte count
  • Blood cell count
  • Immune checkpoint inhibitor
  • Lymphocyte-to-monocyte ratio
  • Neutrophil-to-lymphocyte ratio
  • Platelet-to-lymphocyte ratio

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: A multicenter retrospective study'. Together they form a unique fingerprint.

Cite this